TFX Teleflex Incorporated

Teleflex Awarded National Group Purchasing Agreements with Premier, Inc.

Teleflex Awarded National Group Purchasing Agreements with Premier, Inc.

WAYNE, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded three group purchasing agreements with Premier, Inc. Effective August 1st, 2023, the new agreements allow Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for select Teleflex products in the Laryngoscope Systems, Laryngeal Masks Airways, and Disposable Anesthesia Products categories.

“As a manufacturer of market leading Airway Management products,1 we are delighted to have been awarded these agreements with Premier to provide products that help clinicians deliver the care they expect in order to improve the health and quality of people’s lives,” said Kevin Robinson, President and General Manager, Anesthesia & Emergency Medicine at Teleflex.

Teleflex, through its Rüsch and LMA products, provides healthcare providers solutions to optimize patient outcomes by offering broad portfolios to meet every day airway needs. The group purchasing agreements include access to Rüsch and Sheridan endotracheal tubes, nasal and oral airways, and LMA supraglottic devices.

Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,400 U.S. hospitals and 250,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit .

Teleflex is the home of Arrow, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Reference:

1.2022 IQVIA MDSA data.

Teleflex, the Teleflex logo, Arrow, Deknatel, LMA, Pilling, QuikClot, Rüsch, Sheridan, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are trademarks or registered trademarks of their respective owners. © 2023 Teleflex Incorporated. All rights reserved. MC-009036

Contact:

Teleflex Incorporated:

Lawrence Keusch

Vice President, Investor Relations and Strategy Development



610-948-2836



EN
25/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

 PRESS RELEASE

New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhex...

New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guin...

 PRESS RELEASE

Teleflex Highlights Prostate Health and Quality-of-Life Awareness Thro...

Teleflex Highlights Prostate Health and Quality-of-Life Awareness Through Two Key Public Initiatives During Men’s Health Month Timed with National Men’s Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men1—and encourages them to take control of their health. The Teleflex Prostate Education Express, a mobile training and education center, is on a national tour to educate physicians and the community on prostate health quality-of-life issues associated with BPH and th...

 PRESS RELEASE

Teleflex Publishes 2024 Global Impact Report

Teleflex Publishes 2024 Global Impact Report Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program WAYNE, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2024 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company’s Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB), and Taskforce on Cl...

 PRESS RELEASE

Teleflex Showcases New Clinical Data Presented at the 2025 American Ur...

Teleflex Showcases New Clinical Data Presented at the 2025 American Urological Association (AUA) Annual Meeting Two Head-to-Head Randomized Trials Highlight Superior Early Patient Experience with the UroLift™ System for BPH1-2 First-Ever Analysis Utilizing the American Urological Association Quality Registry (AQUA) to Assess BPH Treatment Modalities Shows Strongest Symptom Improvement Score Shift with UroLift™ System at Three Months.3 First Study to Confirm Safety of Stabilized Hyaluronic Acid (sHA) Rectal Spacer in Cases with Rectal Wall Infiltration (RWI).4 WAYNE, Pa., May 15, 2025 ...

 PRESS RELEASE

New Retrospective Study Reports Significantly Reduced Post-Operative G...

New Retrospective Study Reports Significantly Reduced Post-Operative GERD Rates with the Titan SGS™ Stapler from Teleflex Compared with Multi-Fire Staplers in Sleeve Gastrectomy Data also demonstrate significantly lower rates of postoperative reflux and decreased incidence of de novo gastroesophageal reflux disease (GERD) without affecting total weight loss at 1-year*, and shorter average hospital length of stay (LOS) associated with use of the Titan SGS™ Stapler compared with multi-fire staplers1 WAYNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading g...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch